RIYADH: Global pharmaceuticals company Vifor Pharma Group has signed two joint cooperation agreements with Saudi Pharmaceutical Industries and Medical Appliances Company. The first aims to localize the manufacture of Ferinject, a ferric carboxymaltose preparation that is used intravenously for the treatment of iron deficiency conditions, while the second aims to manufacture and subsequently commercialize ferric carboxymaltose through SPIMACO. The agreements are set for a period of eight years.
According to the terms of the two agreements, Vifor Pharma Group will transfer technology to SPIMACO to produce and manufacture Ferinject for Saudi Arabia, even as it will continue to market it. SPIMACO will also obtain the rights to manufacture and market ferric carboxymaltose in the Kingdom.
Samer Hallak, regional head Middle East and North Africa, Vifor Pharma Group, said: “Vifor Pharma has had a presence in the Kingdom of Saudi Arabia for nearly 30 years, which is a strategic country that is constantly expanding in relation to our company’s products. Our partnership with SPIMACO is based on our commitment to further improving access to innovative medicines in the Kingdom. Most importantly, this investment supports Saudi Arabia’s Vision 2030 by localizing the pharmaceutical industry and ensuring the provision of medicines to patients who need treatment, investing in local manufacturing in addition to creating opportunities for new work.”
Hervé Gisserot, chief commercial officer of Vifor Pharma Group, said: “This milestone reinforces Vifor Pharma’s commitment to Saudi Vision 2030 and the development of local healthcare capabilities in the Kingdom as we aim to contribute to a sustainable ecosystem, which encourages innovation and investment. We look forward to continuing expansion of our local footprint and helping to support areas of high unmet medical need of patients in Saudi Arabia.”
The Ferinject/Injectafer preparation is a leading treatment for iron deficiency, and its use has been approved in 84 countries. The experiences of more than 19 million patients as well as its efficacy and safety have helped to establish it as a trusted brand the world over.
Iron-deficiency anemia occurs as a result of iron deficiency, and it causes many serious consequences for human health, according to the WHO.
Vifor Pharma Group aims to be a leader in iron deficiency, nephrology and cardio-renal therapies.
